Overview
No overview information available.
Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/09/30 | Phase 2 | Not yet recruiting | |||
2024/08/20 | Phase 1 | Recruiting | |||
2024/02/28 | Phase 2 | Not yet recruiting | |||
2023/09/21 | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | ||
2023/05/30 | N/A | Not yet recruiting | |||
2022/08/24 | Phase 2 | Recruiting | |||
2022/07/07 | Phase 2 | UNKNOWN | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | ||
2022/03/14 | Phase 2 | Recruiting | Beijing Sanbo Brain Hospital | ||
2020/04/22 | Phase 4 | UNKNOWN | Hui Bu | ||
2019/09/19 | Phase 2 | UNKNOWN | Guangzhou Institute of Respiratory Disease |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Recombinant Human Endostatin Injection | 国药准字S20050088 | 生物制品 | 注射剂 | 11/13/2019 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.